ワクチン製造委託の世界市場2016-2026...市場調査レポートについてご紹介

【英文タイトル】Vaccine Contract Manufacturing Market Report 2016-2026 : Leading Countries, Technologies and Companies

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 World Vaccine Contract Manufacturing Market Highlights
1.2 Why You Should Read This Report?
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
1.10 Exchange Rates

2. Introduction to Vaccines
2.1 The History of Vaccines
2.2 How Do Vaccines Work?
2.2.1 Artificial Immunity
2.3 Types of Vaccine
2.3.1 Live, Attenuated Vaccines (LAVs)
2.3.2 Recombinant Live Vaccines
2.3.3 Inactivated Vaccines
2.3.4 Toxoid Vaccines
2.3.5 Subunit Vaccines
2.3.6 Conjugate Vaccines
2.3.7 Recombinant Subunit Vaccines
2.3.8 DNA Vaccines
2.3.9 Recombinant Vector Vaccines
2.3.10 Therapeutic Vaccines
2.4 Diseases Preventable with Vaccines
2.5 The Rise of the Vaccines Market
2.6 Technological and Regulatory Improvements

3. Vaccine Manufacturing Technologies, 2015
3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago’s Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax
3.2.6.2 Protein Sciences Corporation (PSC)
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors
3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Pre-Filled Vaccine Products 2015
3.5.3 Drivers and Restraints for Pre-Filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges Flu Vaccines
3.5.4.3 Novartis’ Agriflu and Fluad Ban is Lifted
3.5.4.4 Baxter Flu Vaccine and Side Effects
3.5.4.5 Reported Shelf Life With H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.6.1 Lyophilisation of Vaccines will Increase
3.7 Cell Media Can Improve Virus Yield

4. The Global Vaccine Manufacturing Market 2016-2026
4.1 Overview of the Global Vaccine Manufacturing Market 2016-2026
4.2 World Vaccine Market Forecast 2016-2026
4.3 The Global Vaccine Market By Submarket, 2014 and 2015
4.4 Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
4.5 Paediatric Vaccines Market Overview
4.6 Adult Prophylactic Vaccines Market Overview
4.7 Influenza Vaccines Market Overview
4.8 Therapeutic Vaccines Market Overview

5. The Global Vaccine Contract Manufacturing 2016-2026
5.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
5.1.1 Reasons to Outsource
5.1.2 Benefits of Outsourcing
5.1.3 The Challenges in Outsourcing Vaccine Manufacturing
5.1.4 Why Should Companies Outsource Vaccine Manufacturing?
5.1.5 Strategic Outsourcing vs. Tactical Outsourcing
5.1.6 Virtual Companies
5.2 Contract Manufacturing Organisations (CMOs)
5.2.1 Manufacturing Services Offered by CMOs
5.2.2 Vaccine Manufacturing Activities Typically Outsourced
5.3 The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2016-2026
5.4 Contract Manufacturing Market for Vaccines 2016-2026
5.4.1 Market Size for Contract Manufacturing of Vaccines 2014
5.4.2 Vaccine Contract Manufacturing Market Forecast 2016-2026

6. The Leading National Markets for Vaccine Contract Manufacturing, 2016-2026
6.1 The Leading National Markets for Vaccine Contract Manufacturing
6.2 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2016
6.3 The Leading National Markets for Vaccine Contract Manufacturing, 2016-2026
6.3.1 The US Vaccine Contract Manufacturing Market Forecast, 2016-2026
6.3.2 The EU5 Vaccine Contract Manufacturing Market, 2014 and 2015
6.3.2.1 The EU5 Vaccine Contract Manufacturing Market, 2016-2026
6.3.2.2 The German Vaccine Contract Manufacturing Market, 2016-2026
6.3.2.3 The Italian Vaccine Contract Manufacturing Market, 2016-2026
6.3.2.4 The UK Vaccine Contract Manufacturing Market, 2016-2026
6.3.2.5 The French Vaccine Contract Manufacturing Market, 2016-2026
6.3.2.6 The Spanish Vaccine Contract Manufacturing Market, 2016-2026
6.3.3 The Japanese Vaccine Contract Manufacturing Market, 2016-2026
6.3.4 The Chinese Vaccine Contract Manufacturing Market, 2016-2026
6.3.4 The Indian Vaccine Contract Manufacturing Market, 2016-2026
6.3.5 The Russian Vaccine Contract Manufacturing Market, 2016-2026
6.3.6 The Brazilian Vaccine Contract Manufacturing Market, 2016-2026

7. Leading Vaccine Contract Manufacturing Companies, 2016-2026
7.1 Leading Vaccine Contract Manufacturing Organisations
7.2 Baxter BioPharma Solutions
7.3 Boehringer Ingelheim
7.3.1 Recent Financial Performance
7.3.2 Ben Venue Laboratories
7.3.3 Manufacturing Deals 2011-2015
7.4 Catalent
7.4.1 Recent Financial Performance
7.4.2 Catalent: Financial Performance by Segment, 2011-2015
7.4.3 Catalent Injectable Vaccines
7.4.4 Catalent: Zydis Technology
7.4.5 Regional Market Expansion Strategy
7.5 Charles River Laboratories
7.5.1 Recent Financial Performance, 2011-2014
7.5.2 Financial Performance by Segment, 2010-2015
7.5.3 Recent Financial Performance, 2015
7.5.4 Vaccine Manufacturing Services
7.5.5 Charles River Avian Vaccine Services
7.5.6 Vaccine Manufacturing Expansion
7.5.7 Outlook and Early Stage Restructuring
7.5.8 Partnerships
7.5.8.1 Partnership with AstraZeneca
7.5.8.2 Partnership with Batavia
7.6 IDT Biologika GmbH
7.7 Lonza
7.7.1 Recent Financial Performance
7.7.2 Financial Performance in H1 2015
7.7.3 Manufacturing Division Restructuring
7.8 Meridian Life Science
7.8.1 Recent Financial Performance, 2010-2014
7.8.2 Recent Financial Performance by Segment, 2011-2014
7.8.3 Current Developments, 2015
7.9 Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
7.10 SynCo Bio Partners
7.11.1 Recent Developments
7.11.1.1 Expansion of Facilities
7.11.1.2 FDA Approval of Partner Application

8. Vaccine Manufacturing Market: World Market Trends 2016-2026
8.1 Vaccine Contract Manufacturing Industry Trends
8.2 Strengths
8.2.1 Many Companies Cannot Afford In-house Capabilities
8.2.2 Outsourcing Improves Time to Market
8.2.3 Manufacturers Get Access to Specialised Technologies
8.2.4 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
8.3 Weaknesses
8.3.1 Mass Vaccine Manufacturing Kept In-house
8.3.2 A Highly Fragmented Vaccine Contract Manufacturing Market
8.3.3 An Unpredictable Supply and Demand Business Model
8.4 Opportunities
8.4.1 Many Vaccines in the Product Pipeline
8.4.2 Emerging Market’s Growing Demand for Vaccines
8.4.2.1 Dynamic Change: Emerging Markets are Major Vaccine Developers
8.4.3 Changing World Demographics
8.5 Threats
8.5.1 Post Recession: Biotech Suffer from Severe Cuts in Capital Funding
8.5.2 The Public are Slow to Accept Novel Technologies
8.5.3 Perception of Risk by the Original Vaccine Manufacturers

9. Conclusion
9.1 Overview
9.2 Regulatory and Quality Standards Create High Barriers of Entry
9.3 Emerging Markets Will Show Stronger Growth

10. Glossary


【レポート販売概要】

■ タイトル:ワクチン製造委託の世界市場2016-2026
■ 英文:Vaccine Contract Manufacturing Market Report 2016-2026 : Leading Countries, Technologies and Companies
■ 発行日:2015年12月
■ 調査会社:visiongain
■ 商品コード:VGAIN5122112
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。